About the Authors

Ke Ren

Contributed equally to this work with: Ke Ren, Wei Zhang

Affiliations Medical School and State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China, Jiangsu Laboratory of Molecular Medicine, Medical School, Nanjing University, Nanjing, China

Wei Zhang

Contributed equally to this work with: Ke Ren, Wei Zhang

Affiliations Medical School and State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China, Jiangsu Laboratory of Molecular Medicine, Medical School, Nanjing University, Nanjing, China

Xiaoqing Chen

Affiliation The Hoffmann Institute of Immunology, Guangzhou Medical University, Guangzhou, China

Yingyu Ma

Affiliations Medical School and State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China, Jiangsu Laboratory of Molecular Medicine, Medical School, Nanjing University, Nanjing, China

Yue Dai

Affiliation Jiangsu Laboratory of Molecular Medicine, Medical School, Nanjing University, Nanjing, China

Yimei Fan

Affiliation Medical School and State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China

Yayi Hou

Affiliation Medical School and State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China

Ren Xiang Tan

erguang@nju.edu.cn; rxtan@nju.edu.cn

Affiliations Medical School and State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China, Jiangsu Laboratory of Molecular Medicine, Medical School, Nanjing University, Nanjing, China, Nanjing University of Chinese Medicine, Nanjing, China

Erguang Li

erguang@nju.edu.cn; rxtan@nju.edu.cn

Affiliations Medical School and State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China, Jiangsu Laboratory of Molecular Medicine, Medical School, Nanjing University, Nanjing, China

Competing Interests

The authors have declared that no competing interests exist.

Author Contributions

Conceptualization: EL KR RXT. Formal analysis: EL KR XC. Funding acquisition: EL RXT. Investigation: KR WZ. Methodology: EL KR WZ XC YM. Resources: YH RXT. Software: YF. Supervision: EL. Validation: KR XC YD. Visualization: KR WZ. Writing – original draft: KR EL. Writing – review & editing: EL KR.